AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

NCT04432857 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple-negative Breast Cancer
NSCLC, Squamous or Non-Squamous
Urothelial Carcinoma of the Bladder
Microsatellite Stable (MSS) Colorectal Cancer (CRC)
Cervical Cancer

Interventions

DRUG: AN0025
DRUG: Pembrolizumab

Sponsor

Adlai Nortye Biopharma Co., Ltd.

Collaborators

[object Object]